Data / Drug companies / Mayne Pharma
Mayne Pharma: 26 products in the FDA NDC directory, labeler code 68308
Mayne Pharma (labeler code 68308) lists 26 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 26 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 15, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68308
- Products in commercial distribution
- 26
- Packages
- 31
- Finished drugs by generic name
- 16
- Prescription products
- 26
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1
- Flagged as original packager
- 22 of 22 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- April 26, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 53.8% |
| Authorized generics (NDA) | 10 | 38.5% |
| New drug applications (NDA) | 2 | 7.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Isotretinoin | 8 | 16 |
| Metronidazole | 3 | 68 |
| Tazarotene | 2 | 10 |
| Segesterone acetate and ethinyl estradiol | 1 | 1 |
| Clobetasol propionate | 1 | 40 |
| Clindamycin phosphate and benzoyl peroxide | 1 | 14 |
| Methamphetamine hydrochloride | 1 | 3 |
| Adapalene | 1 | 34 |
| Tretinoin | 1 | 28 |
| Dapsone | 1 | 26 |
| Oxymetazoline hydrochloride | 1 | 64 |
| Ivermectin | 1 | 33 |
| Doxycycline hyclate | 1 | 61 |
| Doxycycline | 1 | 63 |
| Adapalene and benzoyl peroxide | 1 | 11 |
| Halobetasol propionate | 1 | 11 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, liquid filled | 8 | 30.8% |
| Gel | 6 | 23.1% |
| Cream | 4 | 15.4% |
| Aerosol, foam | 2 | 7.7% |
| Ring | 1 | 3.8% |
| Shampoo | 1 | 3.8% |
| Lotion | 1 | 3.8% |
| Tablet | 1 | 3.8% |
| Tablet, delayed release | 1 | 3.8% |
| Capsule | 1 | 3.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rhofade | 68308-766 | Cream | New drug applications (NDA) | July 15, 2026 |
| Clindamycin Phosphate and Benzoyl Peroxide | 68308-127 | Gel | Generic drugs (ANDA) | October 1, 2025 |
| Metronidazole | 68308-711 | Cream | Authorized generics (NDA) | May 19, 2025 |
| Metronidazole | 68308-712 | Lotion | Authorized generics (NDA) | February 10, 2025 |
| Tretinoin (Microsphere) | 68308-777 | Gel | Generic drugs (ANDA) | October 25, 2024 |
| Annovera | 68308-752 | Ring | New drug applications (NDA) | August 16, 2024 |
| Adapalene | 68308-666 | Gel | Authorized generics (NDA) | February 26, 2024 |
| Ivermectin | 68308-701 | Cream | Authorized generics (NDA) | January 8, 2024 |
| Halobetasol propionate | 68308-769 | Aerosol, foam | Generic drugs (ANDA) | November 27, 2023 |
| Metronidazole | 68308-663 | Gel | Authorized generics (NDA) | November 10, 2023 |
| Clobetasol propionate | 68308-664 | Shampoo | Authorized generics (NDA) | November 3, 2023 |
| Doxycycline | 68308-668 | Capsule | Authorized generics (NDA) | February 27, 2023 |
| Dapsone | 68308-342 | Gel | Generic drugs (ANDA) | February 11, 2022 |
| Adapalene and benzoyl peroxide | 68308-662 | Gel | Authorized generics (NDA) | February 1, 2022 |
| Tazarotene | 68308-745 | Cream | Generic drugs (ANDA) | November 10, 2021 |
| Isotretinoin | 68308-573 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 68308-571 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 68308-570 | Capsule, liquid filled | Generic drugs (ANDA) | September 21, 2021 |
| Isotretinoin | 68308-575 | Capsule, liquid filled | Generic drugs (ANDA) | September 3, 2021 |
| Tazarotene | 68308-685 | Aerosol, foam | Authorized generics (NDA) | April 23, 2021 |
| Doxycycline Hyclate | 68308-716 | Tablet, delayed release | Authorized generics (NDA) | February 1, 2016 |
| Isotretinoin | 68308-784 | Capsule, liquid filled | Generic drugs (ANDA) | May 1, 2012 |
| Isotretinoin | 68308-783 | Capsule, liquid filled | Generic drugs (ANDA) | May 1, 2012 |
| Isotretinoin | 68308-782 | Capsule, liquid filled | Generic drugs (ANDA) | May 1, 2012 |
| Isotretinoin | 68308-781 | Capsule, liquid filled | Generic drugs (ANDA) | May 1, 2012 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.